Low dose valproate

ApprovedSmall molecule

Mario Negri Institute for Pharmacological Research

Low dose valproate is one of 95 small molecule programs targeting Nicotine Dependence. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nicotine DependenceActive, not recruiting

Neonatal SeizureActive, not recruiting

EpilepsyActive, not recruiting

Nicotine DependencePhase 2/Phase 3

Active, not recruiting

Neonatal SeizurePhase 1/Phase 2

Active, not recruiting

EpilepsyApproved

Active, not recruiting

Competition

Competitive Landscape

221 competitors in Epilepsy

#DrugCompanyPhaseTrials

Briviact

UCB

Phase 3

14 2

Depacon

AbbVie

Phase 3

1 3

Dayvigo

Eisai

Phase 3

1 4

Fintepla

IImmedica Pharma AB

Phase 3

4 5

Actemra

Roche

Phase 3

—6

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

3 7

Narcan

SScienture

Phase 3

1 8

Immunoglobulin

Sanofi

Phase 3

1 9

Low dose valproate

Mario Negri Institute for Pharmacological Research

Approved

1 10

Carisbamate

SSK Life Science, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Neonatal seizure1 trial

Pharmacokinetic and Safety Trial of Intravenous Levetiracetam in the Treatment of Neonatal Seizures

Completed·RRichard H. Haas·Phase 1/2·NCT00884052·18 enrolled

Nicotine Dependence1 trial

New Treatment for Alcohol and Nicotine Dependence

Completed·UUniversity of Virginia·Phase 2/3·NCT01182766·236 enrolled

Epilepsy1 trial

Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW)

Completed· Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research·Phase 4·NCT03689114·58 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Low dose valproate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Low dose valproate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Low dose valproate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mario Negri Institute for Pharmacological Research company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Mario Negri Institute for Pharmacological Research

Low dose valproate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Neonatal seizure1 trial

Nicotine Dependence1 trial

Epilepsy1 trial

References

Drug Info

Quick Facts

Related News